Correlation Between β-amyloid Deposits Revealed by BF-227-PET Imaging and Brain Atrophy Detected by Voxel-based Morphometry-MR Imaging: a Pilot Study

Overview

Journal Nucl Med Commun

Specialty Nuclear Medicine

Date 2019 Jun 28

PMID 31246935

Citations 2

Authors

Nobuhisa Maeno

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study was to investigate whether β-amyloid (Aβ) deposition was associated with local atrophy of corresponding areas in the brain.

Methods: [11C]2-[2-(2-Dimethylaminothiazol-5-yl) ethenyl-6-[2-(fluoro)ethoxy]benzoxazole (BF-227)-PET, MRI and neuropsychological tests were carried out on 56 subjects, out of which 21 were patients with Alzheimer's disease (AD), 20 were patients with mild cognitive impairment (MCI) and 15 were normal controls (NC). The BF-227 uptake in each local brain region was set up with automated anatomical labeling atlas using Wake Forest University PickAtlas software and local standardized uptake value ratios of BF-227 were calculated as the average value of right and left using the MRIcron software.

Results: Group comparisons of Aβ deposition as determined by BF-227 uptake using PET imaging showed no significant differences between MCI and AD. Aβ deposition was significantly higher in MCI and AD than in NC. The correlation analysis between local Aβ deposition and gray matter atrophy showed that in AD, the Aβ deposition in the inferior temporal gyrus was strongly related to the gray matter atrophy in this region. On the contrary, the Aβ deposition in the precuneus was associated with the atrophy in the right occipital-temporal region. In the NC, the Aβ deposition in the inferior temporal gyrus was associated with the atrophy in the precuneus.

Conclusion: In the AD, the relationship between the Aβ deposition and local atrophy is area-dependent. In NC, Aβ deposition in the inferior temporal gyrus correlated to the atrophy in the precuneus.

Citing Articles

Associating brain imaging phenotypes and genetic risk factors a hypergraph based netNMF method.

Zhuang J, Tian J, Xiong X, Li T, Chen Z, Chen R Front Aging Neurosci. 2023; 15:1052783.

PMID: 36936501 PMC: 10017840. DOI: 10.3389/fnagi.2023.1052783.

An update on magnetic resonance imaging markers in AD.

Leocadi M, Canu E, Calderaro D, Corbetta D, Filippi M, Agosta F Ther Adv Neurol Disord. 2021; 13:1756286420947986.

PMID: 33747128 PMC: 7903819. DOI: 10.1177/1756286420947986.

References

Yankner B, Duffy L, Kirschner D . Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990; 250(4978):279-82. DOI: 10.1126/science.2218531. View

Dore V, Villemagne V, Bourgeat P, Fripp J, Acosta O, Chetelat G . Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol. 2013; 70(7):903-11. DOI: 10.1001/jamaneurol.2013.1062. View

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

Archer H, Edison P, Brooks D, Barnes J, Frost C, Yeatman T . Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol. 2006; 60(1):145-7. DOI: 10.1002/ana.20889. View

Kudo Y . Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease. Minim Invasive Ther Allied Technol. 2006; 15(4):209-13. DOI: 10.1080/13645700600836000. View

Petersen R, Aisen P, Boeve B, Geda Y, Ivnik R, Knopman D . Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013; 74(2):199-208. PMC: 3804562. DOI: 10.1002/ana.23931. View

Driscoll I, Zhou Y, An Y, Sojkova J, Davatzikos C, Kraut M . Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging. 2010; 32(12):2123-30. PMC: 2908199. DOI: 10.1016/j.neurobiolaging.2009.12.008. View

Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T . Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci. 2007; 27(41):10957-68. PMC: 6672864. DOI: 10.1523/JNEUROSCI.0673-07.2007. View

Jack Jr C, Lowe V, Senjem M, Weigand S, Kemp B, Shiung M . 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008; 131(Pt 3):665-80. PMC: 2730157. DOI: 10.1093/brain/awm336. View

10.

Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E . Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56(3):303-8. DOI: 10.1001/archneur.56.3.303. View

11.

Bourgeat P, Chetelat G, Villemagne V, Fripp J, Raniga P, Pike K . Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010; 74(2):121-7. DOI: 10.1212/WNL.0b013e3181c918b5. View

12.

Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M . 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med. 2007; 48(4):553-61. DOI: 10.2967/jnumed.106.037556. View

13.

Chetelat G, Villemagne V, Bourgeat P, Pike K, Jones G, Ames D . Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010; 67(3):317-24. DOI: 10.1002/ana.21955. View

14.

Gross C . Single neuron studies of inferior temporal cortex. Neuropsychologia. 2007; 46(3):841-52. DOI: 10.1016/j.neuropsychologia.2007.11.009. View

15.

Dickson D . Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging. 1997; 18(4 Suppl):S21-6. DOI: 10.1016/s0197-4580(97)00065-1. View

16.

Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron J . Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology. 2003; 60(8):1374-7. DOI: 10.1212/01.wnl.0000055847.17752.e6. View

17.

Fletcher P, Frith C, Baker S, Shallice T, Frackowiak R, Dolan R . The mind's eye--precuneus activation in memory-related imagery. Neuroimage. 1995; 2(3):195-200. DOI: 10.1006/nimg.1995.1025. View

18.

Jack Jr C, Lowe V, Weigand S, Wiste H, Senjem M, Knopman D . Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009; 132(Pt 5):1355-65. PMC: 2677798. DOI: 10.1093/brain/awp062. View

19.

Shao H, Okamura N, Sugi K, Furumoto S, Furukawa K, Tashiro M . Voxel-based analysis of amyloid positron emission tomography probe [C]BF-227 uptake in mild cognitive impairment and alzheimer's disease. Dement Geriatr Cogn Disord. 2010; 30(2):101-11. DOI: 10.1159/000318754. View

20.

Jack Jr C, Knopman D, Jagust W, Shaw L, Aisen P, Weiner M . Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9(1):119-28. PMC: 2819840. DOI: 10.1016/S1474-4422(09)70299-6. View